Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-2402 LAG-MAPS fianlimab plus cemiplimab plus chemotherapy vs cemiplimab plus chemotherapy in treatment-naive pleural mesothelioma
2024-519208-29-00Phase 2Authorised
- Sponsor
- IFCT
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in pleural mesothelioma comparing Fianlimab + cemiplimab + chemotherapy with Cemiplimab + chemotherapy (2 arms). Primary endpoint: Disease Control Rate at 6 months. Planned start Nov 2025; status: authorised.
02
Drugs
fianlimabcemiplimab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2024-519208-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519208-29-00.